Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Subscribe To Our Newsletter & Stay Updated